Navigation Links
Enrollment completed in 2 pivotal phase III studies of the investigational cancer drug vandetanib
Date:3/12/2008

WILMINGTON, Del., March 12, 2008 AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the companys investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC). The two studies ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer) and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) are the second and third of four ongoing studies to complete enrollment. Data from the studies are expected later this year and the broad development program is on track for a first regulatory submission in 2008.

ZODIAC is a randomized, double-blind, international, multi-center Phase III study to assess the efficacy of vandetanib 100mg once-daily plus the standard docetaxel chemotherapy versus docetaxel alone in 1,380 patients with locally advanced or metastatic NSCLC after failure of first-line anti-cancer therapy.

ZEAL is a Phase III parallel group, randomized, double-blind study evaluating vandetanib 100mg once daily plus pemetrexed 500mg/m2 (every 3 weeks) compared with placebo plus pemetrexed as second-line treatment in 510 patients with locally advanced or metastatic NSCLC who have failed first-line anti-cancer therapy.

The ZEST study, which is investigating vandetanib versus erlotinib, was the first Phase III study of vandetanib to complete enrollment in November 2007.

NSCLC is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option that may improve the lives of people with lung cancer, said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZODIAC and ZEAL are part of a broad Phase III clinical trial program designed to gain an understanding of how vandetanib may benefit people with lung cancer.

The other studies are:

  • ZEST (vandetanib versus erlotinib) enrollment is complete; and
    <
    '/>"/>

Contact: Asa Josefsson
asa.josefsson@astrazeneca.com
302-885-4109
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 2 Clinical Trial in Patients With Hepatic Encephalopathy
2. New 2008 Health Plan Directory Features Year-End 2007 Enrollment Data and 4,600 Key Executives
3. Office of Administration Extends Retired State Employees Health Benefits Enrollment Period to March 21
4. Medicares Drug Program Enrollment Up, Costs Down
5. MedicareCRM(TM) Simplifies Annual Enrollment Period for Medicare Health Plans and Beneficiaries
6. Boosts in Managed Care Enrollment Seen Across The Board
7. Devax Announces Completion of Enrollment of DIVERGE Trial of Novel Drug- Eluting Stent System for Bifurcation Lesions
8. Blue Cross Stop Smoking Phone Coaching Enrollments Jumped in October
9. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
10. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
11. Medicare Rx Beneficiaries Urged to Review Changes to Their Drug Plans and Compare with Other Plans During Open Enrollment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... Ebola vaccine appears to be safe and produces an immune ... according to early clinical trial results reported by the U.S. ... I clinical trial for the vaccine paves the way for ... and Sierra Leone as early as January, said Dr. Anthony ...
(Date:11/27/2014)... November 27, 2014 Jeffrey Carlini ... in the Charlotte area providing audits, reviews, compilations, ... to businesses of varying size across numerous industries. ... to meet all of their accounting and tax ... the QuickBooks ProAdvisor Program. When asking Mr. Carlini ...
(Date:11/27/2014)... 2014 VogueQueen.com is making every effort ... across the world. As the premier online supplier of ... proud to release a huge selection of sexy prom ... it is also providing many beautiful styles in its ... at discounted prices. , “VogueQueen.com hopes to provide ...
(Date:11/27/2014)... November 27, 2014 Dr. Ronald Receveur, who ... has a few oral health tips before patients dig into ... Louisville and New Albany affordable cosmetic dentistry, and ... in starch and sugar. While the staff wishes everyone a ... tips for how patients can enjoy a feast that is ...
(Date:11/27/2014)... Allowing children to help with chores while ... give children responsibility, ownership, boosts self-esteem, and above all, helps ... the real question is, how do you encourage your children ... a study published by Child Development Journal, there is. The ... on a child’s willingness to lend a hand. , ...
Breaking Medicine News(10 mins):Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4
... the heart's natural electrical signaling process. The director ... a faculty member in the biomedical engineering department. ... of the human heart have fascinated poets, lovers ... deepest secrets remain tightly locked. Tulane biomechanical engineer ...
... the skin- and flesh-destroying Bairnsdale ulcer has struck a ... publish new recommendations for treating the tropical infection. // ... ulcer, Bairnsdale ulcers are caused by Mycobacterium ulcerans ... tissue, and sometimes bone. ,Associate Professor Paul ...
... scientists at the Vanderbilt Kennedy Center for Research on ... exposure to cocaine and behavioral //and neurological problems in ... Journal of Neuroscience, Gregg Stanwood, Ph.D., and Pat Levitt, ... to cocaine in rabbits, which caused a prolonged displacement ...
... by researchers at the Kimmel Cancer Center at Thomas ... shows that pancreatic cancer patients //65 or older who ... as good a chance as anyone else to live ... records of 890 patients with pancreatic cancer who underwent ...
... can cause subtle but disabling cognitive impairments -- ... Says a recent study by investigators. ... for Research on Human Development may help explain ... prenatal exposure to cocaine. In a recent issue ...
... domestic violence, and health care disparities are among the ... of Nursing (JHUSON) are exploring in efforts to care ... variety of audiences. ,Sick at Heart —JHUSON Associate ... issue of 'moral distress' experienced by many nurses, including ...
Cached Medicine News:Health News:Secrets of the Heart's Signals 2Health News:Skin-Destroying Ulcer Appears in NSW as New Treatment Guidelines Emerge 2Health News:Cocaine During Pregnancy can Cause Behavioral and Neurological Problems in the Child 2Health News:Cocaine During Pregnancy can Cause Behavioral and Neurological Problems in the Child 3Health News:Study: Older Pancreatic Cancer Surgery Survivors Live Long 2Health News:Cocaine's Use During Pregnancy May Cause Lasting Cellular Effects 2Health News:Cocaine's Use During Pregnancy May Cause Lasting Cellular Effects 3Health News:Nurses Ease the Wounded Heart 2Health News:Nurses Ease the Wounded Heart 3Health News:Nurses Ease the Wounded Heart 4
(Date:11/26/2014)... NEW YORK , Nov. 25, 2014 /PRNewswire/ ... with Covidien has been widely discussed in ... but it,s also creating a stronger leading player ... according to Kalorama Information.  The healthcare market research ... monitoring systems will feature a diverse set of ...
(Date:11/26/2014)... -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a designer, manufacturer ... that its Chairman and CEO, Alan Shortall , ... Annual Healthcare Conference at the New York Palace Hotel ... The conference presentation will be broadcast ... To listen, please go to: http://ir.unilife.com/events.cfm . An ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... of choice for certain newly diagnosed patients with chronic myeloid leukemia , ... of cancer cells in 96% of Tasigna patients and reduction of abnormal ... Larger front-line Phase III trial evaluating Tasigna vs. Gleevec(R) now fully accrued ... , EAST HANOVER, N.J., Dec. 8 ...
... SAN FRANCISCO, Dec. 8 Millennium: The ... two large, multi-center,randomized Phase III clinical trials ... of transplant-eligible patients with previously untreated,multiple myeloma ... one study comparing VELCADE and dexamethasone (VcD) ...
Cached Medicine Technology:Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 2Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 3Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 4Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 5Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 6Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 7Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 8Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 9Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 10Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 11Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 12Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia 13Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 2Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 3Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 4Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 5Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 6Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients 7
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
The double action wire cutter has both side and end cutting capabilities....
8 inch Mayo-Hegar needle holder....
... Cancer Camera) a digital special purpose scintimammography ... to image to the edge of the ... chest wall, as well as breast containment ... and surgery, IS2s breast scintimammography camera is ...
Medicine Products: